FINWIRES · TerminalLIVE
FINWIRES

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

By

Danaher (DHR) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.

RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.

Danaher is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.

RBC Capital Markets resumed coverage on Danaher, with an outperform rating and a $200 price target.

Shares of Danaher were down 1.1% in Friday afternoon trading.

Price: $162.75, Change: $-1.79, Percent Change: -1.09%

Related Articles

Australia

DexCom Long-Range Plan Establishes Respectable Base Case, RBC Says

DexCom's (DXCM) long-range plan establishes a respectable base case, but significant total addressable market expansion opportunities could allow the company to notably exceed those targets, RBC Capital Markets said.The company's strategic priorities include remaining the premier glucose sensor for diabetics, setting the standard for customer experience in glucose biosensing, and growing international market share, according to the note Friday.DexCom is targeting over 10% revenue growth annually through 2030, gross margins of 67% to 69%, operating margins of 29% to 30%, adjusted EBITDA margins of 36% to 37%, and free cash flow conversion of 80% to 100% with a commitment toward share repurchases. RBC believes the LRP is conservative and positions the company for potential upside ahead, according to the note.RBC expects 2026 revenue of $5.22 billion, gross margins of 63.5%, operating margins of 23.3% and an EPS of $2.56, all within the company's guidance range. It models 2027 revenue and EPS growth of about 11.9% and 18.2%, respectively.RBC kept an outperform rating on DexCom with a price target of $85.Shares of DexCom rose by nearly 7% in Friday trading.Price: $61.70, Change: $+3.88, Percent Change: +6.71%

$DXCM
Australia

Top Midday Stories: Semiconductor Stocks Down After Trump-Xi Summit; Microsoft Gets Investment From Ackman

All three major US stock indexes were down while US Treasury yields were up in late-morning trading Friday, as investors consider developments from President Donald Trump's summit with Chinese President Xi Jinping.In company news, major semiconductor shares were down after the US-China summit failed to produce any major semiconductor agreements, Yahoo Finance reported. President Trump said China has not approved purchases of Nvidia's (NVDA) H200 AI microchips yet because "they want to develop their own," Bloomberg reported Friday. Nvidia shares were over 3% lower, and Advanced Micro Devices (AMD), Intel (INTC) and ASML (ASML) shares were down 3.3%, 6.3% and 4.6%, respectively.Bill Ackman said Friday on X that his hedge fund, Pershing Square, has made a significant investment in Microsoft (MSFT). Microsoft shares were up 3.5%.Applied Materials (AMAT) reported fiscal Q2 adjusted earnings late Thursday of $2.86 per diluted share, up from $2.39 a year ago, and above the FactSet consensus estimate of $2.68. Revenue was $7.91 billion, up from $7.10 billion a year ago, and above the FactSet consensus of $7.68 billion. For fiscal Q3, the company said it expects adjusted EPS of $3.16 to $3.56 on revenue of $8.45 billion to $9.45 billion. Analysts expect $2.89 and $8.14 billion, respectively. The firm expects its semiconductor equipment business to grow more than 30% in 2026, up from its previous guidance of over 20%, according to the transcript of the company's earnings call. Applied Materials shares were little changed.Shares of Cerebras Systems (CBRS) were down 4% Friday after rising over 98% in the previous day following its Nasdaq debut.Blackstone (BX) and CD&R are in the preliminary stages of exploring offers to acquire Magnum Ice Cream (MICC), Reuters reported Friday, citing sources familiar with the matter. Blackstone shares were down 3.0%, while Magnum was up 9%.Price: $227.99, Change: $-7.75, Percent Change: -3.29%

$AMAT$AMD$ASML$BX$CBRS$INTC$MICC$MSFT$NVDA$STM
Australia

Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a "jewel" at about 4.4x trailing sales, the analyst said.It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said."And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated," the analyst added.RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.Price: $44.78, Change: $+0.04, Percent Change: +0.09%

$TECH